Regeneron Wades Deeper Into Oncology With Ambitions To Be A Force In The Space
Senior VP-global clinical development David Weinreich addresses the company's growing investment in oncology drug development, why Regeneron is well positioned to lead in the area, and business development.
You may also be interested in...
The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.
Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.